A Phase 1 interventional study of vitamin D3 in X-linked Adrenoleukodystrophy, sponsored by Stanford University. Completed at 1 site in United States. Open to male participants aged 18 Months to 25 Years. Per ClinicalTrials.gov, last updated 2022-06-09.
Sponsored by Stanford University · Phase 1, Interventional, and Prevention
In this pilot study, the investigators will assess the safety of two high-dose regimens of oral vitamin D supplementation and measure the effects of vitamin D supplementation on markers of oxidative stress and inflammation in the blood and brain of study participants before, during, and after taking vitamin D supplements.
The goal of the study is to establish research measures (i.e. biomarkers) and an optimal dose for vitamin D supplementation in boys with the X-linked adrenoleukodystrophy (ALD) genotype.
Prior research suggests that higher vitamin D levels in the blood are associated with reduced brain inflammation among individuals with multiple sclerosis, a disease that is similar to the cerebral demyelinating form of ALD. However, serious side effects (e.g. hypercalcemia, kidney stones) can occur if vitamin D levels get too high.
The current study is designed to establish a safe dose of vitamin D for boys with ALD. Although the doses chosen for this study are expected to be safe, the investigators will monitor participants for early signs of vitamin D-related toxicity. The investigators will also examine whether or not vitamin D supplementation affects markers of oxidative stress and inflammation in the blood and brains of ALD boys.
The study requires participants to agree to at least one year of participation. Participants will be asked to take a vitamin D supplement every day, submit blood for analysis every 3 months in the first year, and visit their study center (Stanford University or the Kennedy Krieger Institute) every 6 months throughout the period of study.
Participants will be assigned a vitamin D dose based on bodyweight at entry. Starting doses will include 1,000 or 2,000 international units (IU) of vitamin D3 daily for a 6 month period, followed by a conditional increase to 2,000, 3,000, or 4,000 IU daily thereafter if vitamin D levels have not achieved a target threshold. The vitamin D supplements will be provided by the study. In keeping with the current standard of care for ALD boys aged 18mos - 25 years, participants will need to visit the study site every six months in order to complete a clinic visit and MRI of the brain with gadolinium. As part of this study, however, participants' will need to submit blood work every 3 months during the first year in order for the study investigators to ensure that the participants' calcium and vitamin D levels are in a safe range and to study the effects of vitamin D on markers in the blood. The MRI protocol during the first year will also include one additional sequence (magnetic resonance spectroscopy) in order to measure brain metabolites.
The data generated from this study are intended, in part, to help design a future, large-scale clinical trial to determine whether vitamin D supplementation is capable of reducing the risk of developing the cerebral demyelinating form of ALD.
Criteria for enrollment to screening:
Criteria for assignment to drug:
Exclusion Criteria:
Single-arm, dose-escalation starting at 1,000 IU or 2,000 IU of vitamin D3 daily for a 6 month period, followed by a conditional titration up to 4,000 IU daily for at least 6 months thereafter. No placebo.
Dietary Supplement: vitamin D3
Daily oral supplement provided by study investigators
Also known as: vitamin D
Percent of patients with a plasma 25-OH vitamin D level in the target range (40-80ng/ml) at 12 months
The investigators expect 100% of patients will be in the target range at 12 months (i.e. oral dose of 4000 IU daily)
Time frame: Plasma 25-OH vitamin D will be measured at 12 months
Percent of patients with a plasma 25-OH vitamin D level in the target range (40-80ng/ml) at 6 months
The investigators expect that 80% of patients will be in the target range 6 months (i.e. oral dose of 2000 IU daily)
Time frame: Plasma 25-OH vitamin D will be measured at 6 months
Correlation between appearance of gadolinium enhancing brain lesion on MRI and most recent plasma 25-OH vitamin D level
For participants developing gadolinium enhancing lesions on MRI, the investigators will compare the most recent preceding 25-OH vitamin D level with the average 25-OH vitamin D level of participants in the study who did not develop gadolinium enhancing lesions. The investigators expect the development of gadolinium enhancing lesion on MRI will correlate with lower vitamin D levels. However, our current study is not sufficiently powered to measure this effect.
Time frame: Brain MRI at baseline, 6, 12, 18, 24, 30, and 36 months study enrollment. Plasma 25-OH vitamin D levels at baseline, 3, 6, 9, 12, 18, 24, 30, 36 months of enrollment.
Change in protein carbonyl levels in whole blood at baseline and 12 months.
The investigators expect a decrease in whole blood protein carbonyl levels between baseline and 12 months.
Time frame: Measurements at baseline and 12months
Correlation between plasma 25-OH vitamin D and intracellular glutathione levels in peripheral monocytes
The investigators will use flow cytometry to measure intracellular GSH in CD14+ monocytes from participants peripheral blood at baseline and 12 months. The investigators will measure plasma 25-OH vitamin at the same time points. The investigators expect a positive correlation between plasma vitamin D levels and monocyte GSH levels.
Time frame: Measurements at baseline and 12 months
Change in glutathione (GSH) levels in blood
The investigators expect a positive correlation between plasma 25-OH vitamin levels and GSH levels in whole blood (measured by tandem mass spectroscopy).
Time frame: Measurements will be obtained at baseline, 6months, and 12months
Change in glutathione (GSH) levels in brain
The investigators will examine the correlation between 25-OH vitamin D levels in plasma and total GSH levels in occipital white matter (measured by single-voxel MR spectroscopy).
Time frame: Measurements will be obtained at baseline, 6months, and 12months
Occurrence of serious adverse events
The investigators do not expect any participants to develop hypercalcemia (serum calcium \>10.7mg/dl) or related serious adverse events (e.g. kidney stones) while taking 2000 IU or 4000 IU daily.
Time frame: Measurements will be obtained at baseline, 3months, 6months, 9months, 12months
Change in plasma interleukin-8 levels
The investigators expect a decrease in plasma IL-8 levels between baseline and 12 months
Time frame: Measurements a baseline and 12 months
Change in plasma macrophage inflammatory protein-1b levels
The investigators expect a decrease in plasma MIP-1b levels between baseline and 12 months
Time frame: Measurements at baseline and 12 months
Change in plasma monocyte chemoattractant protein-1 levels
The investigators expect a decrease in plasma MCP-1 levels between baseline and 12 months
Time frame: Measurements at baseline and 12 months
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Deidentified data will be made available to clinical investigators upon reasonable request.
Supporting information: Study protocol, Sap, Icf
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stanford University